Comment
doi: 10.1016/S2352-3018(22)00172-2.
Epub 2022 Jul 19.
Dolutegravir for children with HIV-associated tuberculosis
Affiliations
- PMID: 35868340
- DOI: 10.1016/S2352-3018(22)00172-2
Item in Clipboard
Comment
Dolutegravir for children with HIV-associated tuberculosis
Lancet HIV.
2022 Sep.
No abstract available
Conflict of interest statement
We declare no competing interests.
Comment on
-
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19. Lancet HIV. 2022. PMID: 35868341 Free PMC article. Clinical Trial.
Similar articles
-
The promise of paediatric dolutegravir.J Int AIDS Soc. 2021 Jan;24(1):e25660. doi: 10.1002/jia2.25660. J Int AIDS Soc. 2021. PMID: 33522081 Free PMC article. No abstract available.
-
Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e17-e20. doi: 10.1097/QAI.0000000000002352. J Acquir Immune Defic Syndr. 2020. PMID: 32205722 No abstract available.
-
Compelling evidence for unconditional shift to dolutegravir.Lancet HIV. 2022 Aug;9(8):e523-e524. doi: 10.1016/S2352-3018(22)00164-3. Lancet HIV. 2022. PMID: 35905750 No abstract available.
-
Dolutegravir: first global approval.Drugs. 2013 Sep;73(14):1627-37. doi: 10.1007/s40265-013-0121-4. Drugs. 2013. PMID: 24052331 Review.
-
Is resistance to dolutegravir possible when this drug is used in first-line therapy?Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377. Viruses. 2014. PMID: 25166745 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
